



# Application of Current Technologies in Theranostics for Early-stage Detection of Prostate cancer

Siddharth Goswami <sup>1</sup>, Priya Chamoli <sup>2</sup>, Vijay Jagdish Upadhye <sup>3</sup>, Pallavi Singh\* <sup>4</sup>

## Abstract

Malignant growth, the illness starts when cells in the body begin to grow out of control. Metastatic prostate malignant growth is hopeless, and novel techniques to identify the illness prior to and to coordinate conclusive treatment are required. To combat cancer, microscopically unambiguous methods of restricting radionuclide payloads to malignant cells and surrounding microenvironments are viewed as essential. The execution of theranostic ways to deal with portray and customize patient administration is starting to be acknowledged for prostate disease patients. This composition framed clinically made an interpretation of ways to deal with recognising, describing, and treating sickness in this quickly growing field. Furthermore, theranostics for a microenvironment affected by Bone Metastasis are included with [18F]-FDHT imaging and GRPR Bombesin for the detection of androgen receptors. Quantum Dots (QDs) are semiconductor particles two or three nanometres in size, having optical and electronic properties that differ from greater particles on account of quantum mechanics. Utilization of QDs is similar to the use of minute organic entities killing, damaging cell walls, etc. Besides discussing their properties, such as their ability to kill cancer-causing agents, medications, and effectiveness, various therapeutic approaches are discussed, such as radiation therapy, chemical therapy, chemotherapy, immunotherapy, and ablation. The purpose of artificial intelligence is for a machine to accomplish mental commitments primarily based on measurements provided. Application of Artificial intelligence for Theranostics has been specifically emphasized in this article.

6893

**Key Words:** Prostate Cancer, Thernostics, GRPR Bombesin, AR Imaging, Bone metastasis, Quantum dot, Artificial intelligence

**DOI Number:** 10.14704/nq.2022.20.8.NQ44716

**NeuroQuantology 2022; 20(8):6893-6900**

## Introduction

Cancer, the disease begins when cells in the body start to outgrow control. The carcinogens can spread to almost any body part from anywhere within the body [1,2]. Prostates are small glands that are part of the male reproductive system [3]. This organ may have problems since it produces fluid that enriches semen [4]. The prostate disease starts when cells in the prostate organ begin to outgrow control. The prostate makes a portion of the liquid


that is essential for semen [4]. The prostate is underneath the bladder and before the rectum (the last piece of the digestion tracts) [3]. Original vesicles located behind the prostate produce almost all of the semen liquid. Through the prostate, the urethra completes pee and semen in the body through the penis. The size of the prostate can change as a man ages. In youthful men, it is about the size of a pecan. It very well may be substantially more unmistakable in more established men.

**Corresponding author:** Pallavi Singh

**Address:** <sup>1,2,4</sup>Department of Biotechnology, Graphic Era Deemed to be University, Dehradun, Uttarakhand-248002, <sup>3</sup> Center of Research for Development (CR4D), Dept of Microbiology, Parul Institute of Applied Sciences (PIAS), Parul University, Vadodara Gujarat-391760

E-mail: pallavisingh.bt@geu.ac.in; pallavisingh.22@gmail.com





**Figure 1: Prostate Cancer**

Following the cellular breakdown in the lungs, the prostate disease is the subsequent driving force behind malignant growth passing for men in the United States [6]. In 2021, the number of new prostate malignant growth cases had expected to reach almost 250,000. In opposition to declining death paces of numerous normal tumours, prostate malignant growth passings are ascending, with an increment of 5% from 2019 to 2020. Regardless of the expanded utilization of authoritative treatment over the past ten years has further developed prostate disease explicit endurance, mortality remains exceptionally high, moving toward half in a few examinations.

Even though most prostate tumours develop slowly, they develop rapidly and spread rapidly. It turns out that numerous older men (and, surprisingly, a few younger men) who passed away from different causes also had a prostate disease that did not affect them during their lives. The prostate disease begins as a pre-carcinogenic condition when a man has a prostate biopsy (evacuation of little bits of the prostate to search for malignant growth). Several early symptoms indicate prostate cancer, including consumption or torment during urination, inflammation, enhanced urination in night, loss of bladder control, a diminished stream of urine, swelling of the legs or pelvis, blood in the urine, and semen [5]. "Screening" signifies testing for a sickness regardless of whether you have no side effects. Prostate malignant growth is evaluated with the prostate-specific antigen (PSA) blood test and the digital rectal examination (DRE). This manuscript emphasizes radionuclide theranostics as a way of presenting, screening, and treating prostate malignant growth clinically. The

manuscript presents a concise overview of subatomic imaging and theranostic apparatuses. More than 30,000 prostate cancer deaths were reported in 2019, resulting in enormous individual, cultural, and monetary costs [1].

This manuscript depicts the theranostics of prostate disease which is the utilization of two radioactive medications to distinguish and treat destructive development, with any metastatic growths, related to one radioactive medication. It underlines the Prostate-Specific Membrane Antigen treatment where ligands are set apart with 68Ga or 18F, the job of the Androgen receptor (AR). The gastrin-conveying peptide receptor (GRPR) is imparted on various cell types in higher vertebrates, especially in the tangible framework and gastrointestinal plot. Bone metastases include an enhancement-rich speciality that redesigns the treatment-safe nature of spread development cells have been examined. Traditional imaging modalities, X-shaft enlisted tomography applicate for exact bone sore recognizable proof. Quantum Dots (QDs) are semiconductor particles two or three nanometres in size, having optical and electronic properties that differ from greater particles on account of quantum mechanics. Utilization of QDs is similar to the use of minute organic entities killing, damaging cell walls, etc. Besides discussing their properties, such as their ability to kill cancer-causing agents, medications, and effectiveness, various therapeutic approaches are discussed, such as radiation therapy, chemical therapy, chemotherapy, immunotherapy, and ablation. The purpose of artificial intelligence is for a machine to accomplish mental commitments primarily based on measurements provided. An emphasis has placed on AI's use in PCA.

### Theranostics of Prostate Cancer


Theranostics is a blend of the terms therapeutics and diagnostics. Theranostics is the use of two radioactive drugs to identify and treat cancerous growth, as well as any metastatic tumours, in conjunction with one radioactive drug [7]. Clinical theranostics isolates individuals into groups based on their anticipated reaction, with clinical therapies tailored to each individual. Methodologies like this are sometimes called tailored medication, precise medication, defined medication, or theranostics. Cutting edge prostate malignant growth, the disease that has metastasised and spread to different pieces of the body, frequently the bones term alludes to 177Lutetium PSMA treatment or Prostate-Specific Membrane Antigen treatment. This treatment offers



if treatments like chemicals and chemotherapy have fizzled. It progresses metastatic emasculation safe prostate malignant growth. The goal is to ease the frameworks related to prostate malignant growth instead of a finished fix. The treatment helps by diminishing the size of cancer and preventing them from developing, further developing side effects, and keeping up with and working on personal satisfaction.

The job of atomic imaging utilizing little particle ligands marked with 68Ga or 18F that tight spot to prostate-explicit layer antigen (PSMA) keeps on being characterized for men going through arranging for prostate disease. An enormous precise survey of very nearly 5000 patients reports particularity of >90% and high responsiveness when contrasted and customary imaging among men with biochemical repeat following essential therapy, or men with recently analyzed prostate malignant growth. PSMA (Prostate-Specific Membrane Antigen) is a protein on superficial level cells in the prostate organ. Prostate malignant growth cells, express more PSMA than typical cells.

Further, If the prostate disease cells have spread to different pieces of the body (metastasised), PSMA will likewise be available. 177 Lutetium PSMA treatment utilizes a particle which connects itself to the PSMA receptors on the disease cells. Before it's given to you, the PSMA particle is bound with 177 Lutetium. This is a radioactive substance. It harms and obliterates prostate malignant growth cells in a designated manner, with negligible harm to sound cells. The PSMA particle conveys the 177 Lutetium directly to the cancer site so your entire body isn't presented to radiation. 177 Lutetium PSMA is infused into a vein, goes through the circulatory system and joins itself to prostate malignant growth cells both in the prostate and different locales. This is trailed by a PET/CT examination. The radioactive material presently appended to the disease cells 'illuminates' on the output and shows the area and size of malignant growth sores. Follow the connection for more data on PET CT examines. This data has utilized the phase of the malignant growth and planned treatment. [8]



**Figure 2: PSMA receptor on radio-nuclide selection**

### Androgen Receptor Imaging with [18F]-FDHT

The androgen receptor (AR), an intracellular DNA-restricting, chemical-responsive record factor, is the vital sub-atomic driver for male organ advancement and is the oncological driver of PCa. Actuated by restricting androgens, for example, testosterone in the cytoplasm, the AR then, at that point, moves to the core and animates the statement of qualities associated with separation and multiplication [10]. The viability of stifling this focal AR pathway by androgen-hardship treatment was found by Huggins

a long time back and stays a pillar of PCa treatment [9]. In any case, after an underlying reaction, AR pathway reactivation unavoidably happens, prompting illness movement. As of late grown, a profoundly powerful enemy of androgen particles can be utilized with some impact, even in late-stage, mutilate safe PCa. This shows that AR-flagging keeps up with its focal job over the whole course of infection movement instead of CRPC becoming AR-flagging autonomous. Systems of protection from hostile to androgen treatment in CRPC incorporate



AR-receptor quality enhancement, AR-upregulation, nearby chemical creation, and additionally constitutively dynamic AR-changes [11]. Irrationally, the expression "emasculate safe" most frequently reflects proceeded with androgen reliance, as opposed to advanced AR-pathway autonomy. Hence, even in CRPC sickness, the AR pathway consequently stays a fitting restorative and imaging objective.

FDHT (16\*-[18F]-fluoro-5\*-dihydrotestosterone) is a positron-emitting simple of dihydrotestosterone with the radionuclide [18F] and has been used in little creatures analysis and clinical studies to assess AR-articulation levels and inhabitants [12]. [18F]-FDHT positron outflow tomography (PET) empowers the discovery of metastatic sores, as shown by expanded centralizations of AR, and is being assessed for its ability to aggregate sores working together with other ordinary imaging modalities. Most CRPCs get away from hostile to androgen treatment by AR-flagging intensification, and hormonal treatments that can restrain AR-flagging are a pillar of therapy for CRPCs. Consequently, imaging the articulation levels of AR is a feasible procedure to quantify receptor thickness and the pharmacological reaction to this enemy of androgen treatments.

### GRPR Bombesin

The gastrin-delivering peptide receptor (GRPR) is communicated on an extensive variety of cell types in higher vertebrates, particularly in the sensory system and gastrointestinal plot [13]. Little peptides communicate with GPRP to balance an extensive variety of cell and organ capabilities. GRPR is defiantly overexpressed on the cell surface of numerous diseases, including lung, bosom, and prostate malignant growth. The bombesin subfamily is the best concentrated on GRPR, and countless mammalian and land and water proficient bombesin peptide analogues have been radiolabeled for malignant growth imaging and treatment [15].

A few bombesin radiopharmaceuticals have been tested in people with PCa sickness location in light of the successive overexpression of GRPR, including [68Ga]RM2, [68Ga]BAY86-7548, and [64Cu]-CB-TE2A-AR06. Studies uncover high-contrast discovery of dispersed and essential infection. While GRPR articulation may not be as omnipresent on prostate disease cells as PSMA, there is no foundation target articulation in the kidneys or salivary organs [14]. Hence, there might be the utility for another prostate malignant growth

designated theranostics notwithstanding PSMA, particularly in the GRPR class.

### Theranostics for the Bone Metastasis Microenvironment

The skeletal compartment is the most regular site of metastases in prostate malignant growth patients. These sores are frequently difficult, and may likewise additionally corrupt personal satisfaction through a crack, spinal string pressure, hypercalcemia, and disabled versatility [16]. Bone metastases involve a supplement-rich speciality that upgrades the treatment-safe nature of spread growth cells [17]. Early identification and explicitly restricted therapy of these spread locales are perceived as essential parts of a fruitful procedure to battle bone metastatic prostate malignant growth. Traditional imaging modalities for PCa bone metastases incorporate attractive reverberation and X-beam registered tomography, which is ordinarily applied working together with atomic medication filters for precise bone sore identification. [99mTc]-bisphosphonates and [18F]-NaF are both bone-chasing specialists that are integrated at locales of dynamic bone renovating contiguous metastatic foci and are utilized for imaging. Endorsed beta molecule emanating specialists for bone torment vindication are [89Sr]chloride and [153Sm]EDTMP, a particle and phosphonic corrosive ligand, separately, which are taken up at or close to destinations of bone metastasis. Both produce imageable outflows for planar imaging to assess take-up. Tragically, the long way length of these enthusiastic beta molecule outflows brings about illumination of the bone marrow, a portion restricting organ, and these specialists have not produced endurance enhancements when assessed in clinical preliminary.

As the primary bone-designated radionuclide to conceal pain and increase endurance, it is the alpha-molecule of [223Ra]Cl<sub>2</sub> citrate, known as Xofigo. Radium-223 is a calcium-mimetic and confines to locales of dynamic bone turnover, were it in this way rots, illuminating close by prostate malignant growth cells. The short way lengths of the alpha particles don't bring about frail reactions and the medication is all around endured. While hard to picture, endeavours are in progress to give a quantitative appraisal of 223RaCl<sub>2</sub> conveyance to illuminate assimilated portion measures at locales of sickness and foundation organs. [8]





**Application of QDs**

Quantum Dots (QDs) are semiconductor particles a couple of nanometres in size, having optical and electronic properties that vary from bigger particles because of quantum mechanics. On a few counts, QD appear superior to traditional natural colours, one of the most evident being brilliance. A further application that takes advantage of QD unprecedented photo stability is measurement of atoms and cells' overstretched times of time[18] which accomplish with antibodies, streptavidin, peptides, DNA, nucleic acid aptamers,[19] or small particle ligands[20]. Through inhibition of anti-oxidative structures and downregulation of anti-oxidative properties, QD can kill microscopic organisms. Also, QD can straightforwardly harm the cell wall. QD have been demonstrated to be powerful

against both gram-positive and gram-negative microbes. The utilization of quantum dabs for growth focusing under in vivo conditions utilizes two is focusing on plans: dynamic focusing on and latent focusing on. On account of dynamic focusing, quantum dabs are functionalized with growth explicit restricting locales to tie to cancer cells specifically. Uninvolved focusing involves the upgraded penetration and maintenance of cancer cells for the conveyance of quantum speck tests. Quickly developing cancer cells normally have more penetrable layers than sound cells, permitting the spillage of little nanoparticles into the cell body. In addition, cancer cells come up short on a powerful lymphatic seepage framework, which prompts ensuing nanoparticle collection. Different therapeutics available for prostate cancer

**Table 1. Different therapeutics available for prostate cancer**

S.No.	Therapeutics	Utilization to kill carcinogens	Involvement	Medication used	Efficiency	References
1.	Radiation therapy	High-powered energy	External beam radiation, Brachytherapy	X-rays or protons, rice-sized radioactive seeds	95.5% for intermediate-risk prostate cancer and 91.3% for high-risk prostate cancer.	[21], [22]
2.	Hormone therapy	Prevent body from making the testosterone	Stop testosterone production, block to reach at carcinogen, removal of testicles	LHRH & GnRH, anti-androgen with LHRH, surgery	Most efficient. Used to shrink the cancer and increases the effectiveness of radiation therapy.	[21], [23]
3.	Chemotherapy	Drugs are utilized	Through a vein in your arm, in pill form or both	Drugs injected to treat carcinogen	Cancers that do not respond to hormone therapy.	[21], [32]
4.	Immunotherapy	Immune system	Engineering cells to fight cancer, Immune system identify carcinogens	Sipuleucel-T, Immunotherapy drugs	Cancers that do not respond to hormone therapy.	[24], [33]
5.	Ablative	Destroy	Freezing	Cryoablation	Small prostate	[21],[22]



	therapies	prostate tissue with cold or heat	Prostate Tissue (PT), Heating PT	or cryotherapy, High-intensity focused ultrasound (HIFU)	cancers when surgery isn't possible	
--	-----------	-----------------------------------	----------------------------------	--	-------------------------------------	--

**Artificial Intelligence in Prostate Cancer**

AI is the capability of a machine to carry out cognitive obligations to obtain a specific purpose primarily based on supplied statistics [26]. The digital-based histological analysis (DP) method is a new technique for morphological analysis of glass slides containing tissue sections fixed in formalin and embedded in paraffin. DP will enable the implementation of AI-based algorithms in pathology [27,28]. The most used photo-based AI algorithms are “convolutional neural networks”[29,30]. These algorithms are based on WSI as examine and input institutions and links among objects along with a prognosis made with the aid of a histopathologist, underlying molecular features and sufferers’ survival or response to adjuvant/neoadjuvant remedy, i.e., final results measures [31]. As well as evaluating visible features of tissue, these algorithms can identify microenvironments within tumours, which are not perceived by humans. AI can combine pieces of information derived from several features a good way to make the overall final prognosis. The capabilities are then connected to extra affected person-related records to deliver data of potential price on the behaviour of the disorder, the outcome of the affected person and prediction of reaction to a sure therapeutic approach [26].

PCa analysis is based on the pathological evaluation of prostate biopsies. Blood levels of Prostate Specific Antigen (PSA), the patient's age, co-morbidities, and the presence of the prostate on digital rectal examination are historical factors that guide the decision to recommend a biopsy. The use of PSA remains debatable due to its lack of specificity. Therefore, new serum, urine, and tissue-based biomarkers have emerged however aren't yet considerable in everyday practice [25]. Family records of PCa and genetic predisposition also play a crucial role in the choice to advise PCa early detection. Magnetic Resonance Imaging (MRI) is now part of the PCa analysis pathway and is done before biopsies. However, regardless of the consistent development of its abilities to hit upon PCa, MRI stays a dependent operator and a time-

eating assessment. The equal applies to pathology at the time of biopsy interpretation. Therefore, AI can also play a critical position at numerous steps of the diagnostic pathway.

Applications of ML to prostate most cancers care are rapidly developing thanks to the various technological systems concerned with its prognosis, prognosis and remedy. In diagnostic imaging, ML is implemented to carry out low-degree photo evaluation responsibilities together with prostate segmentation and fusion of different modalities (for example MRI, CT and ultrasonography) and excessive-level inference and prediction obligations consisting of prostate most cancers detection and characterization. ML algorithms are able to beautify prostate cancer remedy by means of augmenting the health care professional’s show with facts which includes cancer localization in the course of robot strategies and different image-guided interventions and might be used toward self sustaining manipulation of tools for assistance inside the operating room. It is possible to do computer-assisted prostate cancer analysis through ML to improve accuracy, reproducibility, and throughput, and to enhance fitness-care transport via custom-designed precision-care pathways. ML strategies are used to pick out genes or groups of genes for which expression specificity to are expecting effects of prostate cancer is excessive and can be used for screening, developing diagnostic tools, figuring out gold standard individualized remedy and producing centered drug regimens. Collaboration among urologists, records scientists, laptop researchers and engineers is required to make sure that AI-based totally choice-help applications are well trained, operated and controlled.

**Conclusion**

Despite the astounding accomplishments in treating metastatic prostate malignant growth throughout recent years, mutilate safe status is viewed as the deadly phase of the illness. Theranostics joins a focus on a compound (ligand) with a helpful radioisotope (radioactive molecule) infused into the



blood to focus on the disease cells. The most considered radioligand is <sup>177</sup>Lu-PSMA-617, which targets PSMA, a protein tracked down in prostate malignant growth cells. This new methodology has shown promising outcomes in treating metastatic mutilation and safe prostate malignant growth. Currently, numerous preliminaries are utilizing PSMA-focusing on radioligands in blend with regular treatments in advanced prostate malignant growth or even in the previous phases of the illness. Researchers are also exploring the possibility of using radioisotopes or ligands with higher specificity and viability to treat prostate disease. Theranostics and PSMA diagnostics are rapidly becoming incorporated into the therapy of patients with prostate disease and starting to use for identifying patients with mCRPC who might benefit from PSMA theranostic treatments. The positive stage 3 VISION study will drive change in the administration of mCRPC and opens the entryway for PSMA theranostics in the initial phases of malignant prostate growth. The next few years will characterize the job of PSMA in symptomatic pathways and as a remedial objective. However, the proof to date upholds PSMA imaging as the norm of care for organizing and prostate disease's limitations.

The initiator of PCa, the androgen receptor, is the driver of prostate adenocarcinoma advancement and can be envisioned with [<sup>18</sup>F] - FDHT. This imaging apparatus can assess the pharmacological effect of enemies of androgens and their adequacy. Cell surface antigen-designated specialists, specifically PSMA-designated urea-based ligands and antibodies, have now been surveyed in a great many situations to identify and treat metastatic prostate disease. Imminent clinical preliminaries that are as of now selecting or in progress will give more clear data on the utility of these new theranostic ways to deal with work on personal satisfaction and general endurance. These specialists can convey ablative portions to locales of infection all through the body with the possibility to conquer this as of now hopeless illness. Contrasts in the imaging properties and helpful speciality for various atomic substances and radionuclides are of proceeding with research interest to give ideal patient-explicit analytic data and remedial results.

## References

- Siegel RL, Miller KD, Jemal A. Cancer statistics (2018). *CA Cancer J Clin.* (2018) 68:7–30. 10.3322/caac.21442 [PubMed]
- "Cancer". World Health Organization. 12 September 2018
- Young, Barbara; O'Dowd, Geraldine; Woodford, Phillip (2013). Wheater's functional histology: a text and colour atlas (6th ed.). Philadelphia: Elsevier. pp. 347–8. ISBN 9780702047473.
- Barrett, Kim E. (2019). Ganong's review of medical physiology. Barman, Susan M., Brooks, Heddwen L., Yuan, Jason X.-J. (26th ed.). New York. pp. 411, 415. ISBN 9781260122404. OCLC 1076268769.
- Davidson's 2018, pp. 437–9.
- Rawla P (April 2019). "Epidemiology of Prostate Cancer". *World J Oncol (Review)*. 10 (2): 63–89. doi:10.14740/wjon1191. PMC 6497009. PMID 31068988.
- Kalash R.S., Lakshmanan V.K. (2016). 4.4 – Theranostics. *Biomaterials Nanoarchitectonics*. Philadelphia: Elsevier. Pp 197-215. <https://doi.org/10.1016/B978-0-323-37127-8.00012-1>.
- Abou D, Benabdallah N, Jiang W, Peng L, Zhang H, Villmer A, Longtine MS, Thorek DLJ. Prostate Cancer Theranostics - An Overview. *Front Oncol.* 2020 Jun 5;10:884. doi: 10.3389/fonc.2020.00884. PMID: 32582550; PMCID: PMC7290246.
- Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic prostate glands of dogs. *Cancer Res.* (1941) 1:293–8.
- Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. *Cancer Metastasis Rev.* (2014) 33:399–411. 10.1007/s10555-013-9471-3.
- Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. In: *Urologic Oncology: Seminars and Original Investigations*. New York, NY: Elsevier; (2007). 10.1016/j.urolonc.2006.09.018.
- Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, et al. Specific <sup>18</sup>F-FDHT accumulation in human prostate cancer xenograft murine models is facilitated by prebinding to sex hormone-binding globulin. *J Nucl Med.* (2018) 59:1538–43. 10.2967/jnumed.118.208785.
- Sunday ME, Kaplan LM, Motoyama E, Chin WW, Spindel ER. Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. In: *Pathology Reviews*. Totawa, NJ: Humana Press; (1989). p. 54–7. 10.1007/978-1-4612-4502-5\_4.
- Iagaru A. Will GRPR compete with PSMA as a target in prostate cancer? *J Nucl Med.* (2017) 58:1883–4. 10.2967/jnumed.117.198192.
- Ramos-Álvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, et al. Insights into bombesin receptors and ligands: highlighting recent advances. *Peptides.* (2015) 72:128–44. 10.1016/j.peptides.2015.04.026.
- Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. *Hum Pathol.* (2000) 31:578–83. 10.1053/hp.2000.6698.
- Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. *J Mol Med.* (2015) 93:1203–12. 10.1007/s00109-015-1329-4.
- Dahan, M. (2003). "Diffusion Dynamics of Glycine Receptors Revealed by Single-Quantum Dot Tracking". *Science.* 302 (5644): 442–5. Bibcode:2003Sci...302..442D. doi:10.1126/science.1088525. PMID 14564008. S2CID 30071440.



- .Dwarakanath, S.; Bruno, J. G.; Shastry, A.; Phillips, T.; John, A.; Kumar, A.; Stephenson, L. D. (2004). "Quantum dot-antibody and aptamer conjugates shift fluorescence upon binding bacteria". *Biochemical and Biophysical Research Communications*. 325 (3): 739–43. doi:10.1016/j.bbrc.2004.10.099. PMID 15541352.
- Zherebetskyy D.; Scheele M.; Zhang Y.; Bronstein N.; Thompson C.; Britt D.; Salmeron M.; Alivisatos P.; Wang L.W. (2014). "Hydroxylation of the surface of PbS nanocrystals passivated with oleic acid". *Science* [Submitted manuscript]. 344 (6190): 1380–1384. Bibcode:2014Sci...344.1380Z. doi:10.1126/science.1252727. PMID 24876347. S2CID 206556385.
- Georgi Pirtskhalaishvili md; phd,Ronald L. Hrebinko md; Joel B. Nelson md (2008). "The Treatment of Prostate Cancer.". Online Willey Library; Volume9, Issue6: <https://doi.org/10.1111/j.1523-5394.2001.96009.pp.x>.
- Gay HA, Michalski JM. Radiation Therapy for Prostate Cancer. *Mo Med*. 2018 Mar-Apr;115(2):146-150. PMID: 30228707; PMCID: PMC6139853.
- Willet F.WhitmoreJr (1956). Hormone therapy in prostatic cancer. Volume 21, Issue 5, November 1956, Pages 697-713 [https://doi.org/10.1016/0002-9343\(56\)90086-9](https://doi.org/10.1016/0002-9343(56)90086-9).
- Marijo Bilusic; Ravi A. Madan; James L. Gulley. (2017). Immunotherapy of Prostate Cancer: Facts and Hopes. Volume 23, Issue 22. <https://doi.org/10.1158/1078-0432.CCR-17-0019>.
- Brönimann, S.; Pradere, B.; Karakiewicz, P.; Abufaraj, M.; Briganti, A.; Shariat, S.F. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. *Expert Rev. Mol. Diagn.* 2020, 1–10.
- Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. *Nat Rev Urol* 2019;16:391-403. [Crossref] [PubMed]
- Rakha EA, Toss M, Shiino S, et al. Current and future applications of artificial intelligence in pathology: a clinical perspective. *J Clin Pathol* 2020; Epub ahead of print. [Crossref] [PubMed]
- Moradi M, Salcudean SE, Chang SD, et al. Multiparametric MRI maps for detection and grading of dominant prostate tumors. *J Magn Reson Imaging* 2012;35:1403-13. [Crossref] [PubMed]
- Krizhevsky A, Sutskever I, Hinton GE. ImageNet classification with deep convolutional neural networks. *Commun ACM* 2017;60:84-90. [Crossref]
- LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature* 2015;521:436-44. [Crossref] [PubMed]
- Janowczyk A, Madabhushi A. Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases. *J Pathol Inform* 2016;7:29.
- Nader R, El Amm J, Aragon-Ching JB. Role of chemotherapy in prostate cancer. *Asian J Androl*. 2018 May-Jun;20(3):221-229. doi: 10.4103/aja.aja\_40\_17. PMID: 29063869; PMCID: PMC5952475.
- Fernández-García, E.M., Vera-Badillo, F.E., Perez-Valderrama, B. et al. Immunotherapy in prostate cancer: review of the current evidence. *Clin Transl Oncol* 17, 339–357 (2015). <https://doi.org/10.1007/s12094-014-1259-6>

